CURRENT
ISSUE
1609

Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in hospitalized patients. An earlier EUA limited use of the drug to patients hospitalized with severe disease.1

MECHANISM OF ACTION — Remdesivir is a nucleotide prodrug of an adenosine analog that inhibits viral replication by binding to RNA-dependent RNA polymerase. It is active against SARS-CoV-2 and some other coronaviruses in vitro and in animal models.

CLINICAL STUDIES — In one clinical trial in 1062 patients...  Continue reading

More from Issue 1609
Previous Issue: 1608      October 5, 2020
Coming Soon
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
In Brief: New Benzodiazepine Warnings
Large-Volume, Preservative-Free Albuterol Concentrate
Drugs for Asthma
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on ... Continue reading

 Tweets